A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants

Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients

(2018) Marin M. Jukić et al.   AMERICAN JOURNAL OF PSYCHIATRY

A genetic risk score is differentially associated with migraine with and without aura

(2017) Claudia Pisanu et al.   HUMAN GENETICS

DGIdb 3.0: a redesign and expansion of the drug–gene interaction database

(2017) Kelsy C Cotto et al.   NUCLEIC ACIDS RESEARCH

A Genetic Risk Score Is Associated with Weight Loss Following Roux-en Y Gastric Bypass Surgery

(2016) Marcus Bandstein et al.   OBESITY SURGERY

LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants: Fig. 1.

(2015) Mitchell J. Machiela et al.   BIOINFORMATICS

Genome-wide association data classification and SNPs selection using two-stage quality-based Random Forests

(2015) Thanh-Tung Nguyen et al.   BMC GENOMICS

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6andCYP2C19Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

(2015) JK Hicks et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The combined effect of genetic polymorphisms and clinical parameters on treatment outcome in treatment-resistant depression

(2015) Alexander Kautzky et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

The impact ofCYP2C19polymorphisms on citalopram metabolism in patients with major depressive disorder

(2015) Z. Uckun et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Identifying genetic loci associated with antidepressant drug response with drug–gene interaction models in a population-based study

(2015) Raymond Noordam et al.   JOURNAL OF PSYCHIATRIC RESEARCH

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders. Part 2: Maintenance Treatment of Major Depressive Disorder-Update 2015

(2015) Michael Bauer et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys

(2015) R. C. Kessler et al.   Epidemiology and Psychiatric Sciences

Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations

(2014) Yuan Ji et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

TNF-α, IL-6, and Leptin Increase the Expression of miR-378, an Adipogenesis-Related microRNA in Human Adipocytes

(2014) Lu-lian Xu et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

Insight into the Effects of Adipose Tissue Inflammation Factors on miR-378 Expression and the Underlying Mechanism

(2014) Xinye Jiang et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis

(2014) Ming Chang et al.   CLINICAL PHARMACOKINETICS

A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances

(2014) E Peñas-Lledó et al.   PHARMACOGENOMICS JOURNAL

Stability in symptoms of anxiety and depression as a function of genotype and environment: a longitudinal twin study from ages 3 to 63 years

(2014) M. G. Nivard et al.   PSYCHOLOGICAL MEDICINE

Common Genetic Variation and Antidepressant Efficacy in Major Depressive Disorder: A Meta-Analysis of Three Genome-Wide Pharmacogenetic Studies

(2013) et al.   AMERICAN JOURNAL OF PSYCHIATRY

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

(2013) J K Hicks et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The Genotype-Tissue Expression (GTEx) project

(2013) John Lonsdale et al.   NATURE GENETICS

Drugs, genes and the blues: Pharmacogenetics of the antidepressant response from mouse to man

(2013) Olivia F. O'Leary et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

PGC-1 coactivators in the control of energy metabolism

(2011) C. Liu et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP

(2011) Patricia Huezo-Diaz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Systems biology data analysis methodology in pharmacogenomics

(2011) Andrei S Rodin et al.   PHARMACOGENOMICS

CYP2C19 variation and citalopram response

(2010) David A. Mrazek et al.   Pharmacogenetics and Genomics

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response

(2010) Ming-Hsien Tsai et al.   PHARMACOGENOMICS

The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors

(2009) Martin Preisig et al.   BMC Psychiatry

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

(2009) Alain Li-Wan-Po et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A genome-wide association study points to multiple loci predicting antidepressant treatment outcome in depression

(2009) M Ising et al.   PHARMACOPSYCHIATRY

The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome

(2008) Mathieu Firmann et al.   BMC Cardiovascular Disorders

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

(2008) Staffan Ohlsson Rosenborg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Genes mirror geography within Europe

(2008) John Novembre et al.   NATURE